SCHEMBL9922220

SCHEMBL9922220

COc1ccc2[nH]cc(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3Cl)c(=O)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
LMNA P02545 5/20 0.40
GALR3 O60755 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
TP53 P04637 2/20 0.39
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 1/20 0.37
PDE4B Q07343 1/20 0.36
FBP1 P09467 1/20 0.36
NR4A2 P43354 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 2/20 0.36
HTR2C P28335 1/20 0.36
NLRP3 Q96P20 1/20 0.36
STING1 Q86WV6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161710 0.93 MEN1 (0.47) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL9923253 0.90 MAPT (0.41) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL9922908 0.88 DHODH (0.42) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL12177423 0.88 STING1 (0.46) MAPTLMNASTING1
SCHEMBL12161715 0.85 MEN1 (0.46) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL9923257 0.85 HTR2C (0.43) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL14113780 0.85 MEN1 (0.46) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL13633804 0.83 P2RY12 (0.43) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL12161691 0.83 MEN1 (0.49) MAPTLMNAGALR3ALDH1A1MEN1
SCHEMBL12161720 0.79 MEN1 (0.46) MAPTLMNAGALR3ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 MAPT 4832/4885LMNA 3576/4885GALR3 2019/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 MAPT 4832/4885LMNA 3603/4885GALR3 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.